skip to main content
media conference

Press Releases

  • February 15, 2017

    Multiple Myeloma Announcement

    New Brunswick-led national research team aims for tailored treatments for patients with incurable multiple myeloma through Terry Fox Research Institute's $5-million investment.

  • February 15, 2017

    Cambridge MP Bryan May congratulates TFRI and partners in House of Commons

    In the House of Commons today, Cambridge MP Bryan May congratulated TFRI and its joint pilot project partners -- The Princess Margaret Cancer Centre and the BC Cancer Agency -- for their new partnership to accelerate precision medicine. You can listen to his remarks on You Tube or read them below.

  • February 02, 2017

    The Terry Fox Research Institute, Princess Margaret Cancer Centre and BC Cancer Agency launch innovative pilot project to accelerate precision medicine in Canada

    The Terry Fox Research Institute and two leading cancer centres in Canada -- the Princess Margaret Cancer Centre and the BC Cancer Agency -- have launched an innovative pilot project to accelerate precision medicine for their cancer patients.

  • January 04, 2017

    Inexpensive algorithm will increase accuracy in subclassification of ovarian cancer, aid in matching treatment to histotype

    A biomarker study by COEUR (Canadian Ovarian Experimental Unified Resource), TFRI’s pan-Canadian ovarian cancer research team, examining over 2,000 ovarian cancer tissue samples has led to the development of an inexpensive immunohistochemical algorithm for classifying the five different disease subtypes.

  • January 03, 2017

    Hypoxia team members make game-changing findings about how tumour cells control oxygen consumption

  • January 03, 2017

    TFRI-funded team identifies two new inhibitors that show potential in combination therapies for adult brain cancer

    A study by TFRI researchers investigating potential new drugs to treat glioblastoma (GBM) patients has identified an epigenetic-modifier drug which, taken in combination with standard chemotherapy, extends life in mouse models. Further, a second inhibitor that limits tumour growth and shows no toxicity to cells may also hold promise as a treatment therapy.

  • January 03, 2017

    How differences in the germline influence the type of prostate cancer that arises

    When it comes to treating prostate cancer, the news is predominantly positive: a combination of early detection and treatment by radiotherapy and surgery mean that most patients will not die of the disease. Still, its incidence continues to rise and prostate cancer remains the most frequently diagnosed non-skin malignancy in Canadian men.

  • January 03, 2017

    Personalizing treatment for patients with the most common malignant childhood brain tumour

  • January 03, 2017

    Clusterin knockdown sensitizes prostate cancer cells to therapies by modulating mitosis

    A study by a TFRI-funded team based at the Vancouver Prostate Centre has found that silencing a key driver of castrate-resistant prostate cancer and regulating cell division (mitosis) can improve patient drug response.

  • December 14, 2016

    Whole genome sequencing study helps BC team learn how aggressive follicular lymphoma occurs in patients

    Follicular lymphoma (FL), the second most common form of non-Hodgkin lymphoma, is a largely incurable disease of B cells, yet in many cases, because of its indolent nature, survival can extend to well beyond 10 years following diagnosis. Yet in a small number of cases, histological transformation - where fast-growing cells outnumber the smaller, slow-growing cells - or early progression to aggressive lymphoma occurs.

  • December 08, 2016

    Stem cell-based test predicts leukemia patients' response to therapy to help tailor treatment

    TORONTO, Canada – Dec. 7, 2016 – Leukemia researchers at Princess Margaret Cancer Centre, with funding from Terry Fox and others, have developed a 17-gene signature derived from leukemia stem cells that can predict at diagnosis if patients with acute myeloid leukemia (AML) will respond to standard treatment.

  • December 08, 2016

    Ontario Node Symposium in Toronto draws large crowd; images posted

    TFRI's Ontario Node Research Symposium held on Monday, December 5 in Toronto drew over 400 people this year from across the province and beyond to hear a variety of interesting talks on the theme of Innovating Towards Transformative Cancer Care.

  • November 16, 2016

    Children from local school pay special visit to TFRI headquarters

    TFRI's office in Vancouver, BC welcomed some special guests last month with the visit of three children from the Grade 1 class at St. John's School. The trio, along with a parent and a caregiver, were here to visit with Darrell Fox, Terry's younger brother, who shared with them books and stories about Terry.

  • September 29, 2016

    2016 Terry Fox Run update: TFRI teams show immense support, with over $105,000 raised through team/t-shirt challenge

    TFRI-funded research teams from coast to coast showed their true colours this year, turning out by the dozens in researcher-designated purple T-shirts and forming teams to raise funds for cancer research at the 36th Terry Fox Run on Sunday Sept. 18. Early estimates show the research community's fundraising efforts resulted in over $105,000 raised.

  • September 29, 2016

    Groundbreaking study finds miR-126 regulates distinct self-renewal outcomes in normal and malignant hematopoietic stem cells

    A groundbreaking new publication by Dr. John Dick’s TFRI-funded team has confirmed that miRNA expression patterns are predictive of disease outcome in leukemia, and play a powerful role in governing the fundamental properties that define the “stemness” state of human leukemia stem cells (LSCs).

Back to Top